Siloam International Hospital (SILO IJ)
Operational Growth Momentum Remains Intact Despite Higher Financing Costs
- SILO sustained its revenue growth momentum in 3Q26, supported by higher patient volume, revenue intensity, and private-payer contribution.
- First REITs’ first tranche transaction completed, covering eight hospital properties and approximately 59% of total transaction value.
- Maintain Buy rating with a lower TP of Rp2,500 following earnings revisions; We believe SILO’s long-term growth outlook remains intact.
Sustained Growth Momentum with Improving Margins
SILO sustained its growth momentum in 3Q26, with revenue increasing by 7% qoq to Rp3.7tr, while EBITDA margin improved to 31.7% (vs. 30.0% in 3Q25 and 29.6% in 2Q26). Operationally, both volume and revenue intensity continued to expand, with IP days/OP visits increasing by 4%/5% qoq and 2%/4% yoy, while IP revenue per day/OP revenue per visit grew by 4%/0.4% qoq and 14%/3% yoy. This was accompanied by a continued shift towards private payers, whose contribution to total revenue increased to 84.9% (vs. 83.5% in 3Q25), while BPJS contribution declined to 15.1% (vs. 16.5% in 3Q25). The solid top-line growth and margin expansion translated into 3Q26 net profit of Rp348bn (+16% qoq; +14% yoy), bringing 9M26 earnings to Rp929bn (+22% yoy), equivalent to 75% of both our and cons. FY26F estimates, in line with expectations.
First REITs Transaction Progresses with Tranche 1 Completion
The first tranche of SILO’s First REITs transaction, comprising eight hospital properties, was successfully completed between Sep-Oct26, with a transaction value of ~Rp4.1tr (~59% of the total transaction value). The remaining six properties, with an estimated transaction value of Rp2.8tr, are expected to be completed under the second tranche by 1Q27. For FY26, management guided for a reduction in rental expenses of approximately Rp80bn, partly offset by additional depreciation of Rp45bn and higher interest expenses of Rp150bn. Beyond the financial impact, full ownership of the acquired properties provides SILO with greater flexibility in managing, renovating, and expanding its hospital facilities.
We Lowered our FY26/27F Earnings Est. by 7/17%
SILO will continue to prioritize private payers and revenue intensity through higher-acuity cases, specialist recruitment, and the development of Centers of Excellence, supporting our unchanged revenue forecasts. Meanwhile, following the completion of the first tranche of the First REITs transaction and the anticipated completion of the second tranche in 1Q27, we lower our FY26F/27F net profit estimates by 7%/17%, primarily reflecting higher financing costs. The additional depreciation expense is largely offset by the elimination of existing rental expenses.
Maintain Buy rating with a lower TP of Rp2,500
We maintain our Buy rating with a lower TP of Rp2,500 (previously Rp2,850), reflecting our earnings forecast revisions. We believe SILO’s long-term growth outlook remains intact despite near-term earnings dilution from the First REITs transaction. Key risks include higher financing costs, softer patient volumes, and weaker revenue intensity.
… Read More 20261112 SILO


